Compare ULH & LCTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ULH | LCTX |
|---|---|---|
| Founded | 1932 | 1990 |
| Country | United States | United States |
| Employees | N/A | 77 |
| Industry | Trucking Freight/Courier Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 462.1M | 388.6M |
| IPO Year | 2004 | 1996 |
| Metric | ULH | LCTX |
|---|---|---|
| Price | $24.20 | $1.50 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 4 |
| Target Price | ★ $20.00 | $6.25 |
| AVG Volume (30 Days) | 44.4K | ★ 1.0M |
| Earning Date | 05-12-2026 | 05-14-2026 |
| Dividend Yield | ★ 1.74% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,461,708,000.00 | $14,556,000.00 |
| Revenue This Year | $2.73 | $109.40 |
| Revenue Next Year | $5.12 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 53.24 |
| 52 Week Low | $12.78 | $0.43 |
| 52 Week High | $30.76 | $2.09 |
| Indicator | ULH | LCTX |
|---|---|---|
| Relative Strength Index (RSI) | 63.68 | 43.20 |
| Support Level | $23.19 | $1.44 |
| Resistance Level | $25.85 | $1.80 |
| Average True Range (ATR) | 1.48 | 0.08 |
| MACD | -0.04 | -0.01 |
| Stochastic Oscillator | 71.68 | 18.33 |
Universal Logistics Holdings Inc is an asset-light provider of customized transportation and logistics solutions throughout the United States, and in Mexico, Canada and Colombia. It offers services such as truckload, brokerage, intermodal, dedicated, and value-added services. The company reports into four segments namely trucking, intermodal, company-managed brokerage, and contract logistics. The majority of the revenue is earned from the contract logistics segment.
Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline currently includes: OpRegen, OPC1, ReSonance, ILT1, RND1, PNC1, and LCT-CON. Its programs are based on its proprietary, in-house, cell-based manufacturing platform, which it call AlloSCOPE (Allogeneic, Scalable, Consistent, Off-the-shelf, Pluripotent Cell Engineering), and supported by its associated development, formulation, manufacturing, and delivery capabilities. The AlloSCOPE platform is a proprietary differentiation and production modality from which, a single, well-characterized pluripotent cell line can create a stable current Good Manufacturing Practice, master cell bank.